These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

428 related items for PubMed ID: 23256518

  • 41. Cladribine to Treat Relapsing Forms of Multiple Sclerosis.
    Giovannoni G.
    Neurotherapeutics; 2017 Oct; 14(4):874-887. PubMed ID: 29168160
    [Abstract] [Full Text] [Related]

  • 42. Effects of cladribine tablets on heart rate, atrio-ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosis.
    Hermann R, Litwin JS, Friberg LE, Dangond F, Munafo A.
    Br J Clin Pharmacol; 2019 Jul; 85(7):1484-1494. PubMed ID: 30883839
    [Abstract] [Full Text] [Related]

  • 43. Real-world use of cladribine tablets (completion rates and treatment persistence) in patients with multiple sclerosis in England: The CLARENCE study.
    Brownlee W, Amin A, Ashton L, Herbert A.
    Mult Scler Relat Disord; 2023 Nov; 79():104951. PubMed ID: 37639781
    [Abstract] [Full Text] [Related]

  • 44. A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study.
    Giovannoni G, Boyko A, Correale J, Edan G, Freedman MS, Montalban X, Rammohan K, Stefoski D, Yamout B, Leist T, Aydemir A, Borsi L, di Cantogno EV.
    Neurodegener Dis Manag; 2023 Oct; 13(5):261-268. PubMed ID: 37535336
    [Abstract] [Full Text] [Related]

  • 45. Oral pulsed therapy of relapsing multiple sclerosis with cladribine tablets - expert opinion on issues in clinical practice.
    Stangel M, Becker V, Elias-Hamp B, Havla J, Grothe C, Pul R, Rau D, Richter S, Schmidt S.
    Mult Scler Relat Disord; 2021 Sep; 54():103075. PubMed ID: 34261026
    [Abstract] [Full Text] [Related]

  • 46. Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: post hoc analysis of subgroups with and without prior disease-modifying drug treatment.
    Vermersch P, Galazka A, Dangond F, Damian D, Wong SL, Jack D, Harty G.
    Curr Med Res Opin; 2021 Mar; 37(3):459-464. PubMed ID: 33331183
    [Abstract] [Full Text] [Related]

  • 47. Effects of Postponing Treatment in the Second Year of Cladribine Administration: Clinical Trial Simulation Analysis of Absolute Lymphocyte Counts and Relapse Rate in Patients with Relapsing-Remitting Multiple Sclerosis.
    Terranova N, Hicking C, Dangond F, Munafo A.
    Clin Pharmacokinet; 2019 Mar; 58(3):325-333. PubMed ID: 29992396
    [Abstract] [Full Text] [Related]

  • 48. Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis-A systematic review and network meta-analysis.
    Bartosik-Psujek H, Kaczyński Ł, Górecka M, Rolka M, Wójcik R, Zięba P, Kaczor M.
    Mult Scler Relat Disord; 2021 Apr; 49():102769. PubMed ID: 33516133
    [Abstract] [Full Text] [Related]

  • 49. Evaluation of Patient-Reported Outcomes in Patients with Relapsing Multiple Sclerosis Treated with Cladribine Tablets in the CLAWIR Study: 12-Month Interim Analysis.
    Rau D, Müller B, Übler S.
    Adv Ther; 2023 Dec; 40(12):5547-5556. PubMed ID: 37776477
    [Abstract] [Full Text] [Related]

  • 50. Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis.
    Siddiqui MK, Khurana IS, Budhia S, Hettle R, Harty G, Wong SL.
    Curr Med Res Opin; 2018 Aug; 34(8):1361-1371. PubMed ID: 29149804
    [Abstract] [Full Text] [Related]

  • 51. Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis.
    Afolabi D, Albor C, Zalewski L, Altmann DR, Baker D, Schmierer K.
    Mult Scler; 2018 Oct; 24(11):1461-1468. PubMed ID: 28817997
    [Abstract] [Full Text] [Related]

  • 52. Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5 years: a plain language summary.
    Stefano N, Sormani MP, Giovannoni G, Rammohan K, Leist TP, Coyle PK, Dangond F, Alexandri N, Galazka A.
    Neurodegener Dis Manag; 2022 Dec; 12(6):303-310. PubMed ID: 36017797
    [Abstract] [Full Text] [Related]

  • 53. Cladribine tablets for relapsing-remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study.
    Rammohan K, Giovannoni G, Comi G, Cook S, Rieckmann P, Soelberg Sørensen P, Vermersch P, Hamlett A, Kurukulasuriya N, CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) Study Group.
    Mult Scler Relat Disord; 2012 Jan; 1(1):49-54. PubMed ID: 25876451
    [Abstract] [Full Text] [Related]

  • 54. Fingolimod for relapsing multiple sclerosis: an update.
    Horga A, Castilló J, Montalban X.
    Expert Opin Pharmacother; 2010 May; 11(7):1183-96. PubMed ID: 20367536
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets.
    Schmierer K, Wiendl H, Oreja-Guevara C, Centonze D, Chudecka A, Roy S, Boschert U.
    Neurodegener Dis Manag; 2023 Feb; 13(1):15-21. PubMed ID: 36545912
    [Abstract] [Full Text] [Related]

  • 57. Disease stability over five years in people with multiple sclerosis treated with cladribine tablets: a plain language summary.
    Giovannoni G, Comi G, Rammohan K, Rieckmann P, Dangond F, Jack D, Vermersch P.
    Neurodegener Dis Manag; 2022 Dec; 12(6):295-301. PubMed ID: 36017780
    [Abstract] [Full Text] [Related]

  • 58. Cladribine as a therapeutic option in multiple sclerosis.
    Warnke C, Leussink VI, Goebels N, Aktas O, Boyko A, Kieseier BC, Hartung HP.
    Clin Immunol; 2012 Jan; 142(1):68-75. PubMed ID: 21733757
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine.
    Warnke C, Wiendl H, Hartung HP, Stüve O, Kieseier BC.
    Drug Des Devel Ther; 2010 Jul 21; 4():117-26. PubMed ID: 20689698
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.